Calprotectin instability may lead to undertreatment in children with IBD

Autor: Anneke C. Muller Kobold, Lucie Wagenmakers, Sjoukje-Marije Haisma, Patrick F. van Rheenen
Přispěvatelé: Center for Liver, Digestive and Metabolic Diseases (CLDM), Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Archives of Disease in Childhood
Archives of Disease in Childhood, 105(10), 996-998. BMJ PUBLISHING GROUP
ISSN: 1468-2044
0003-9888
Popis: BackgroundTreatment decisions in children with inflammatory bowel disease (IBD) are increasingly based on longitudinal tracking of faecal calprotectin concentrations, but there is little known about the stability of this protein in stool.MethodsWe stored aliquots of homogenised stool at room temperature and at 4°C, and measured the calprotectin concentration for 6 consecutive days with three different assays. In addition, we assessed calprotectin stability in assay-specific extraction buffers kept at room temperature.ResultsAfter 6 days of storage at room temperature, mean percentage change from baseline calprotectin concentrations in stool and extraction buffer was 35% and 46%, respectively. The stability of calprotectin was significantly better preserved in samples stored at 4°C (p=0.0066 and 0.0011, respectively).ConclusionsCalprotectin is not stable at room temperature. Children with IBD and their caretakers may be falsely reassured by low calprotectin values. The best advisable standard for preanalytical calprotectin handling is refrigeration of the stool sample until delivery at the hospital laboratory.
Databáze: OpenAIRE